Table 2.
Characteristics, efficacy, and safety data from selected clinical trials of anti-BCMA CAR T cell constructs in RRMM.
| CAR Construct | Study Name | Antigen | Number of Patients | High Risk/EMD (%) | CR (%) | CRS (%) | Neurotoxicity (%) | NCT Number | References |
|---|---|---|---|---|---|---|---|---|---|
| Ide-cel (bb2121) | CRB-401, Phase 1 | BCMA | 62 | 27/37 | 39 | 76 | 36 | NTC02658929 | [71] |
| Ide-cel (bb2121) | KarMMa, Phase 2 | BCMA | 128 | 35/39 | 33 | 84 | 18 | NCT03361748 | [74,75] |
| Cilta-cel (LCAR-B38M) | LEGEND-2, Phase 1/2 | Biepitope to BCMA (VHH1 and VHH2) | 57 | NR | 74 | 90 | 1 | NCT03090659 | [76] |
| Cilta-cel (JNJ-4528) | CARTITUDE-1, Phase 1b/2 | Biepitope to BCMA (VHH1 and VHH2) | 97 | 24/13 | 80 | 95 | 21 | NCT03548207 | [77,78] |
| Orva-cel (JCARH125) | EVOLVE, Phase 1/2 | BCMA | 62 | 41/23 | 36 | 89 | 13 | NCT03430011 | [79] |
| bb21217 | CRB-402, Phase 1 | BCMA | 69 | 33/NR | 29 | 70 | 16 | NCT03274219 | [80] |
| CAR-BCMA | Phase 1 | BCMA | 24 | 46/NR | 8 | 71 | NR | NCT02215967 | [81,82] |
| UPenn-CART-BCMA | Phase 1 | BCMA | 25 | 96/28 | 8 | 88 | 32 | NCT02546167 | [83] |
| CT053 | LUMMICAR STUDY 2, Phase 1b/2 | BCMA | 20 | 55/25 | 25 | 79 | 16 | NCT03915184 | [84] |
| ALLO-715 | UNIVERSAL, Phase 1 | BCMA | 31 | 48/23 | VGPR: 40 | 45 | 0 | NCT04093596 | [73] |
| C-CAR088 | Phase 1 | BCMA | 23 | 81/NR | 44 | 91 | 4 | NCT03751293 NCT03815383 NCT04322292 NCT048295018 | [85] |
CAR = chimeric antigen receptor, EMD = extra-medullary disease, CR = complete remission, CRS = cytokine release syndrome, NR = not reported, VGPR = very good partial remission, and BCMA = B cell maturation antigen.